Pharma Stocks

Earnings Tell The Story For Hanmi Pharm. Co., Ltd. (KRX:128940)

When close to half the companies in Korea have price-to-earnings ratios (or “P/E’s”) below 14x, you may consider Hanmi Pharm.…

Read More »

Pharma, Specialty Units Likely to Drive Cardinal Health’s Q2 Earnings

Cardinal Health, Inc. CAH is scheduled to report second-quarter fiscal 2026 results on Feb. 05, before market open. In the…

Read More »

Ascletis Pharma (SEHK:1672) Is Up 5.4% After HK$844m Follow-On Offering And Positive Phase III Acne Data – Has The Bull Case Changed?

Ascletis Pharma recently filed a follow-on equity offering of HK$843.54 million via a subsequent direct listing, issuing 69,256,000 ordinary shares…

Read More »

Pharma Stock Skyrockets After Reporting 1,135% YoY Net Profit Growth

Synopsis: NGL Fine Chem Limited reports 43.11% YoY revenue growth and a 1,135.43% YoY surge in net profit in Q3…

Read More »

Aurobindo Pharma Ltd. Exhibits Mildly Bullish Momentum Am…

Price Momentum and Recent Performance The stock closed at ₹1,226.15 on 4 Feb 2026, marking a significant day change of…

Read More »

Terns Pharmaceuticals (TERN) Valuation Check After Expanded Global Rights To TERN-701

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply…

Read More »

Liminatus Pharma (LIMN) jumps in premarket after late-session spike as Nasdaq $1 rule hangs over shares

New York, Feb 3, 2026, 07:20 (EST) — Premarket Shares of Liminatus Pharma surged roughly 29% in early premarket action.…

Read More »

Mankind Pharma Sees Sharp Open Interest Surge Amid Bullis…

Open Interest and Volume Dynamics The latest data reveals that Mankind Pharma’s open interest (OI) rose from 12,857 contracts to…

Read More »

Promising 199% Upside Potential For Biotech Investors

Telix Pharmaceuticals Limited (TLX), an Australian biotechnology company, is making waves in the healthcare sector with its innovative approach to…

Read More »

Defensive Pharma Giant Tests Investor Patience as Shares Drift Near Lows

Takeda Pharmaceutical’s U.S.-listed ADR has slipped toward the lower end of its 52-week range, even as the Japanese drug maker…

Read More »